Jobs
View more job listings or post a job
Gate Bioscience Director of Toxicology
Nura Bio Director of Toxicology
Nura Bio Vice President of CMC
MilliporeSigma Emerging Biotech Market Development Manager - San Fransisco
How Cancer LLC Social Media Digital Marketing Specialist  
How Cancer LLC Syndicated National Writer - Cancer 
University of California, Davis SCREENING SUPERVISOR
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Post a job

Workshop

Webcast: Conducting Clinical Trials in China – Regulatory and Clinical Challenges and Recent Developments for Drug and Device Development; Lessons for US-based Companies Entering the China Market


Speakers: Lan Huang (BeyondSpring); John Mao (Foresee Pharma); Vivian Mao (Abbott Vascular); Honggang Bi (Covance China); Guobin Wang (PPD China)
Organizers:
Date: 2017-09-21
Time: 14:00-16:30 Pacific Time
Registration fee: (USD):
Location: Online Webcast ONLY
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2017-09-21  (it will close sooner if the seating cap is reached)

About the Topic

Pharmaceutical and Medical Device companies today face a growing demand to expand their clinical trial programs into China in order to access the vast pool of patients. While there are clear benefits for conducting clinical trials in China, there are significant operational and regulatory challenges, which need to be addressed before overseas companies plan to conduct trials in China, either as a trial conducted solely in China or as part of a multinational trial involving Chinese patients. It is important that appropriate measures are put in place to satisfy the ever evolving Chinese clinical trial and approvability standards. In the meantime, the China FDA (CFA) has initiated a major effort to harmonize the regulatory and clinical practices with the developed world and has implemented a number of policies that have profound impact on the clinical and regulatory practices in China.

This workshop aims at discussing some of the regulatory and operational challenges when conducting clinical trials in China, in both, the Pharma and Medical device arena. The presenters who are industry leaders with deep experience with drug and device development in China will review some of the recent regulations for the Pharma and Device development in China and suggest ways to approach China’s FDA (CFDA). It will discuss challenges and solutions when conducting national or multinational device trials in China from the perspectives of a local Chinese CRO as well as global CROs with affiliates in China. The workshop will provide examples for early strategies to include China in the development as part of a global development plan. A case example will demonstrate how a global clinical Phase 3 trial would suffice for a US FDA and China FDA approval.


About the Speakers

Lan Huang, PhD, BeyondSpring (Co-founder & CEO) 
John Mao, PhD, Foresee Pharma (SVP) 
Vivian Mao, MD, Abbott Vascular (Associate Director, Clinical Science) 
Honggang Bi, PhD, Covance China (Corporate Vice President and General Manager) 
Guobin Wang, PhD, PPD China (Director, Project Management)


2025-02-13, [Free Online] The Science and Stories of Promising Biotech Startups
2025-02-26, [In-Person] Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
2025-03-07, [In-Person] Clinical Trial Planning and Conduct: Fundamentals, Strategies and Best Practices
2025-03-27, [Free Online Workshop] Biotech Financing 101: from Angels, Government Agencies, Foundations and VCs
2025-04-01, [For vendors ONLY] Seattle PBSS Seminar Luncheon Vendor Show
2025-04-09, [In-Person] Cell Therapy Discovery and Development: Fundamentals, Strategies and Best Practices (jointly by PBSS and RAPS-SF)
2025-04-22, [Free Online Workshop] Career Transitions for Research Scientists: BD/Sales in CROs, CDMOs, and Lab Products & Instruments
2025-04-25, [In-Person] Drug Metabolism Fundamentals and Metabolite Identification
2025-05-05, [Free Online] Highlights of 2024 FDA Drug Approvals
2025-05-12, [In-Person] Preclinical Pharmacology Studies and Translational Medicine for Drug Discovery and Development
2025-06-02, [In-Person] Metabolism and Transport-mediated Drug-Drug Interaction: Current Practices, Regulatory Guidances, and Their Impact on Drug Development
©Pharmaceutical & BioScience Society, International; Last Modified: 2/12/2025; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Allucent Experts bringing development innovation w/ClinPharm Modeling & Simulation deliverables to inform dose, study design, modeling+development strategies.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Submit a Text Ad